In 2002, San Francisco voters passed the ‘Care Not Cash’ initiative. Its intent was to stop giving cash directly to homeless individuals, assuming they would waste it on drugs and alcohol. However, during the same period, researchers were paying individuals who used drugs substantial amounts to participate in studies.
Conventional beliefs suggested that these payments funded relapse. Yet, evidence shows funds were mainly used for rent, food, and bills. The development of new treatments hinges on participants having the time and resources to engage in research.
Studies focused on the combination of buprenorphine and naloxone, now known as Suboxone. These were conducted with active heroin users. The federal government is investigating the legality of paying clinical trial participants. The HHS Office of Inspector General solicited feedback on whether such payments should be protected, with comments due by August 24.
For decades, payment legality existed in a gray area due to an anti-kickback statute. This statute penalizes offering incentives to Medicare and Medicaid patients. The concern is that reimbursing these beneficiaries could seem like an inducement to use reimbursable services, even if those costs are routine.
Bioethics considerations highlight fears that money might influence decisions, especially among vulnerable individuals. However, studies show that cash payments do not increase drug use or impair consent. Participants often state that they would participate without monetary inducements.
Research also indicates that higher payments improve attentiveness to risk disclosures. In 2021, trials showed that financial incentives did not skew how participants evaluated risks or skew demographics toward poorer applicants. Justice and scientific integrity dictate that trials include the populations they aim to help.
Suboxone’s existence stems from research involving active opioid users. The rules around participant payments aim to avoid exploitation by overpaying. Yet, underpaying or excluding participants exploits them too.
The inspector general should establish guidelines for reimbursing actual out-of-pocket costs and compensating time, considering the demands of the study. Hard caps may limit study protocols or exclude needed participants.
Repeating ‘Care Not Cash’ logic in clinical research overlooks that trial participation is work, requiring punctuality, protocol adherence, and sometimes even physical risk. Current Medicaid work requirements should recognize this, linking trial participation with work that addresses poverty-related diseases.
The inspector general’s decisions should align with evidence, not outdated fears. Learning from the success of Suboxone trials emphasizes the need to support those willing to contribute to scientific advancement; their involvement is crucial for saving lives.